Physician No program year No payments reported Source: CMS Open Payments, 2026 publication

Martin Gomez

General Practice Hialeah, FL

NPI 1134671290 CMS profile 4413417

2750 W 68Th St Ste 127, Hialeah, FL 33016

Open in the dashboard

General payments

$0

None reported

Research payments

$0

Paid to them · None reported

Ownership & investment interest

$0

None reported

The CMS Open Payments record contains no reported payments to Martin Gomez of Hialeah, FL.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

Prescribing to Medicare patients

Part D · data year 2024 · 195 drugs

Part D claims

30,601

Median for General Practice: 1,105

Drug cost

$743,393

Median for General Practice: $48,734

Branded share of claims

19.6%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dapagliflozin Dapagliflozin Propanediol Brand 212 $107,487
Tadalafil Generic 523 $74,039
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 268 $36,581
Eliquis Apixaban Brand 63 $34,854
Entresto Sacubitril/Valsartan Brand 49 $31,434
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 411 $26,455
Xarelto Rivaroxaban Brand 43 $23,372
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 185 $19,868
Saxagliptin-Metformin Er Saxagliptin Hcl/Metformin Hcl Brand 55 $19,760
Insulin Glargine-Yfgn Generic 176 $18,999

The 10 drugs with the highest cost, of 195 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Other General Practice in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record